Komplementärmedizin (KAM) in der gynäkologischen Onkologie

Zusammenfassung

Tumoren aus dem Bereich der gynäkologischen Onkologie haben in der Regel eine günstige Prognose, da sie meist in Frühstadien erkannt werden. Dennoch nutzen gynäkologisch-onkologische Patientinnen, insbesondere Brustkrebspatientinnen, die Möglichkeiten der komplementären und alternativen Medizin. Derzeit erfolgt diese Behandlung weitgehend ohne einen rationalen Hintergrund. Inzwischen liegen aber einzelne situationsbezogene und entitätsspezifische Studien vor, die eine Beratung auf rationaler Ebene ermöglichen. Diese sollten im Hinblick auf die Wirksamkeit und die Sicherheit stärker berücksichtigt werden.

Summary

Carcinomas from the field of gynaecologic oncology are generally associated with a favourable prognosis as most of them can be detected quite early. In spite of these favourable chances many patients, especially breast cancer patients, use the treatment possibilities of complementary and alternative medicine. However, the current treatment recommendations mostly are not based on a rational background. Meanwhile there are several studies which allow a reasonable consultation on the topic. These should be recognised.

Gynäkologische Tumoren - Komplementärmedizin (KAM) - Onkologie

gynaecologic carcinomas - complementary medicine (CAM) - oncology

Literatur

• 01 Beuth J, Ost B, Pakdaman A, Rethfeld E, Bock P R, Hanisch J, Schneider B. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients - results of an epidemiological multicentre retrolective cohort study.  Cancer Chemother Pharmacol. 2001;  47 Suppl.: S45–54
• 02 Bohm S, Battista Spatti G, Di Re F, Oriana S, Pilotti S, Tedeschi M, Tognella S, Zunino F. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma.  Anticancer Res. 1991;  11 1613-1616
• 03 Bardy J, Slevin N J, Mais K L, Molassiotis A. A systematic review of honey uses and its potential value within oncology care.  J Clin Nurs. 2008;  17 2604-2623
• 04 Chan M M, Soprano K J, Weinstein K, Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.  J Cell Physiol. 2006;  207 389-396
• 05 Di Re F, Bohm S, Oriana S, Spatti G B, Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer.  Cancer Chemother Pharmacol. 1990;  25 355-360
• 06 Duskova M, Wald M. Orally administered proteases in aesthetic surgery.  Aesthetic Plast Surg. 1999;  23 41-44
• 07 Ernst E, Schmidt K, Baum M. Complementary/Alternative therapies for the treatment of breast cancer. A systematic review of randomized clinical trials and a critique of current terminology.  Breast J. 2006;  12 526-530
• 08 Fujitani T. Influence of proteolytic enzymes on permeation of antibiotics into maxillary sinus membrane of patients with chronic sinusitis.  Otorhinic Clinic. 1973;  66 557-565
• 09 Frenkel G D, Caffrey P B. A prevention strategy for circumventing drug resistance in cancer chemotherapy.  Curr Pharm Des. 2001;  7 1595-1614
• 10 García-Closas R, Castellsagué X, Bosch X, González C A. The role of diet and nutrition in cervical carcinogenesis. a review of recent evidence.  Int J Cancer. 2005;  117 629-637
• 11 Goodwin P J, Ennis M, Pritchard K I, Koo J, Trudeau M E, Hood N. Diet and breast cancer. evidence that extremes in diet are associated with poor survival.  J Clin Oncol. 2003;  21 2500-2507
• 12 Hernandez-Reif M, Ironson G, Field T, Hurley J, Katz G, Diego M, Weiss S, Fletcher M A, Schanberg S, Kuhn C, Burman I. Breast cancer patients have improved immune and neuroendocrine functions following massage therapy.  J Psychosom Res. 2004;  57 45-52
• 13 Horneber M A, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev; 2008 (2) CD003297
• 14 Howat R C L, Lewis G D. The effect of bromelain therapy on episiotomy wounds. A double-blind controlled clinical trial.  Obstet Gynaecol. 1972;  77 365-368
• 15 Grossarth-Maticek R, Ziegler R. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.  Arzneimittelforschung. 2007;  57(10) 665-78
• 16 Koyama A, Mori J, Tokuda H, Waku M, Anno H, Katayama T, Murakami K, Komatsu H, Hirata M, Arai T et al.. Augmentation by serrapeptase of tissue permeation by cefotiam.  Jpn J Antibiot. 1986;  39 761-771
• 17 Labourey J L. Physical activity in the management of cancer-related fatigue induced by oncological treatments.  Ann Readapt Med Phys. 2007;  50 445-454
• 18 Larsson S C, Wolk A. Tea consumption and ovarian cancer risk in a population-based cohort.  Arch Intern Med. 2005;  165 2683-2686
• 19 Lesperance M L, Olivotto I A, Forde N, Zhao Y, Speers C, Foster H, Tsao M, MacPherson N, Hoffer A. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer. an historical cohort study.  Breast Cancer Res Treat. 2002;  76 137-143
• 20 Li Z, Carrier L, Belame A, Thiyagarajah A, Salvo V A, Burow M E, Rowan B G. Combination of methylselenocysteine with tamoxifen inhibits MCF-7 breast cancer xenografts in nude mice through elevated apoptosis and reduced angiogenesis.  Breast Cancer Res Treat. 2008;  118 33-43
• 21 Li Z, Carrier L, Rowan B G. Methylseleninic acid synergizes with tamoxifen to induce caspase-mediated apoptosis in breast cancer cells.  Mol Cancer Ther. 2008;  7 3056-3063
• 22 Lissoni P, Tancini G, Paolorossi F, Mandala M, Ardizzoia A, Malugani F, Giani L, Barni S. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin. a phase II study.  J Pineal Res. 1999;  26 169-173
• 23 Locatelli M C, D'Antona A, Labianca R, Vinci M, Tedeschi M, Carcione R, Corbo A, Venturino P, Luporini G. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity.  Tumori. 1993;  79 37-39
• 24 Moolenaar M, Poorter R L, van der Toorn P P, Lenderink A W, Poortmans P, Egberts A C. The effect of honey compared to conventional treatment on healing of radiotherapy-induced skin toxicity in breast cancer patients.  Acta Oncologica. 2006;  45 623-624
• 25 Münstedt K Hrsg.. Ratgeber unkonventionelle Krebstherapien. 2. Aufl. Landsberg: Ecomed; 2005
• 26 Nagel G, Hoyer H, Katenkamp D. Use of complementary and alternative medicine by patients with breast cancer. observations from a health-care survey.  Support Care Cancer. 2004;  12 789-796
• 27 Nagle C M, Purdie D M, Webb P M, Green A, Harvey P W, Bain C J. Dietary influences on survival after ovarian cancer.  Int J Cancer. 2003;  106 264-269
• 28 Oh W K, Kantoff P W, Weinberg V, Jones G, Rini B I, Derynck M K, Bok R, Smith M R, Bubley G J, Rosen R T, DiPaola R S, Small E J. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.  J Clin Oncol. 2004;  22 3705-3712
• 29 Sartippour M R, Pietras R, Marquez-Garban D C, Chen H W, Heber D, Henning S M, Sartippour G, Zhang L, Lu M, Weinberg O, Rao J Y, Brooks M N. The combination of green tea and tamoxifen is effective against breast cancer.  Carcinogenesis. 2006;  27 2424-2433
• 30 Seely D, Oneschuk D. Interactions of natural health products with biomedical cancer treatments.  Curr Oncol. 2008;  15 Suppl 2:s109.es81–10.es86
• 31 Shah Y M, Al-Dhaheri M, Dong Y, Ip C, Jones F E, Rowan B G. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.  Mol Cancer Ther. 2005;  4 1239-1249
• 32 Shannon J, Thomas D B, Ray R M, Kestin M, Koetsawang A, Koetsawang S, Chitnarong K, Kiviat N, Kuypers J. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand.  Cancer Causes Control. 2002;  13 691-699
• 33 Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.  Gynecol Oncol. 2004;  93 320-327
• 34 Seely D, Mills E J, Wu P, Verma S, Guyatt G H. The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer. a systematic review and meta-analysis.  Integr Cancer Ther. 2005;  4 144-155
• 35 Semiglazov V F. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.  Anticancer Res. 2006;  26 1519-1529
• 36 Shord S S, Shah K, Lukose A. Drug-botanical interactions. a review of the laboratory, animal, and human data for 8 common botanicals.  Integr Cancer Ther. 2009;  8 208-227
• 37 Smyth J F, Bowman A, Perren T, Wilkinson P, Prescott R J, Quinn K J, Tedeschi M. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin. results of a double-blind, randomised trial.  Ann Oncol. 1997;  8 569-563
• 38 Vadgama J V, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.  Anticancer Res. 2000;  20 1391-1414
• 39 Verhoef M J, Balneaves L G, Boon H S, Vroegindewey A. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients. a systematic review.  Integr Cancer Ther. 2005;  4 274-286
• 40 Willich S N, Girke M, Hoppe J-D, Kiene H, Klitzsch W, Matthiessen P F, Meister P, Ollenschläger Günter, Heimpel H. Schulmedizin und Komplementärmedizin: Verständnis und Zusammenarbeit müssen vertieft werden.  Dtsch Ärztebl. 2004;  101 A-1314-1319
• 41 van der Zee J, van Rhoon G C. Cervical cancer. radiotherapy and hyperthermia.  Int J Hyperthermia. 2006;  22 229-234

Korrespondenzadresse